Endocrine — approved in some markets
Tesamorelin 5 mg
A GHRH analogue approved in certain markets for a specific, narrowly defined clinical indication under prescription and specialist oversight.
What it is
Tesamorelin is a synthetic growth-hormone-releasing-hormone analogue. It holds regulatory approval in some jurisdictions for a specific prescription indication; approval does not extend to general wellness or body-composition use.
Mechanism being studied
Stimulates endogenous growth-hormone release via GHRH receptor agonism.
Human evidence
Randomised controlled trials support its approved indication in the populations studied. Evidence outside that approved indication is limited and does not support general use.
Safety considerations
As a prescription medicine in the markets where it is approved, it requires clinical assessment, monitoring and prescriber oversight. Contraindications and interactions apply. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.
Regulatory status
Approved in some jurisdictions under prescription; registration status in South Africa must be confirmed with SAHPRA. Prescription-only where registered.
Certificate of analysis
Third-party analytical documentation for this compound is published for transparency and professional review. It confirms identity and purity of tested material only, and is not a marketing authorisation, a registration, or a recommendation for use.
View certificate (PDF)Key references
- Regulator-approved product information in markets where registered.
- Randomised controlled trials supporting the approved indication.
References are provided as reading directions for professionals. They do not constitute endorsement of any use.
Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.
South Africa — compliance notice
SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.